The at-home, non-prescription version of the Covid-19 antigen test has received approval. Credit: Phase Scientific International.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Phase Scientific International’s INDICAID COVID-19 Rapid Antigen At-Home Test (INDICAID OTC).

The test obtained authorisation for non-prescription, at-home use.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Now that it is available across the US, people in the country will be able to perform the test on-demand.

INDICAID is a lateral flow immunoassay that has been designed for the detection of SARS-CoV-2 antigens from anterior nasal swab specimens collected from individuals with or without Covid-19 symptoms.

The samples may be self-collected by individuals aged 14 years and above. Adults can collect samples from individuals aged two years and above.

The Covid-19 rapid antigen at-home test takes 20 minutes to complete.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It showed strong performance, with accuracy in identifying 85% of Covid-19 positive people (PPA) and 97% of those negative (NPA) for the virus from self-collected samples in a prospective multi-site clinical study conducted in the US.

Phase Scientific founder and CEO Dr Ricky Chiu said: “The professional version of INDICAID has been widely adopted and utilised in the US to meet a variety of emergency testing needs. From schools, mobile testing sites, urgent care networks and hospitals.

“We see the approval of INDICAID OTC for non-prescription home testing to expand the adoption of our product to everyone’s daily life and further support our fight against the pandemic.”

In July 2020, the company obtained CE Mark approval for its PHASIFY Viral RNA extraction kit.

Following this approval, Phase Scientific expanded the commercialisation of its test kits to the European Union and other countries as part of the fight against Covid-19.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact